Clinical Trial Update: Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients [Phase 1]

View source ↗

Summary

Phase 1 trial assessing tolerability, immunogenicity, and preliminary efficacy of HB-110 delivered by electroporation in adults with chronic hepatitis B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• HB-110

Snippet

Sponsor: Genexine, Inc. | Conditions: Hepatitis B, Chronic | Phase 1 | Status: COMPLETED